NRX Pharmaceuticals (NRXP) Cash from Financing Activities (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Cash from Financing Activities data on file, last reported at $3.4 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 54.86% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $19.1 million, a 30.26% increase from a year earlier, with the FY2025 full-year figure at $23.3 million, up 210.97% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $3.4 million, down from $4.6 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for NRXP reached as high as $23.0 million in Q1 2022 and fell as low as -$1.5 million in Q3 2023.
• Historically, Cash from Financing Activities has averaged $4.3 million across 5 years, with a median of $2.5 million in 2023.
• Across the five-year window, Cash from Financing Activities surged 1012100.0% in 2022 and plunged 5260.71% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $10.1 million in 2022, then sank by 111.03% to -$1.1 million in 2023, then surged by 269.8% to $1.9 million in 2024, then surged by 141.42% to $4.6 million in 2025, then slipped by 25.16% to $3.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $3.4 million in Q1 2026, $4.6 million in Q4 2025, and $9.7 million in Q3 2025.